Differences in facial emotion recognition between bipolar disorder and other clinical populations: A systematic review and meta-analysis
Michele De Prisco,Vincenzo Oliva,Giovanna Fico,Laura Montejo,Chiara Possidente,Lorenzo Bracco,Lydia Fortea,Gerard Anmella,Diego Hidalgo-Mazzei,Michele Fornaro,Andrea de Bartolomeis,Alessandro Serretti,Andrea Murru,Eduard Vieta,Joaquim Radua
DOI: https://doi.org/10.1016/j.pnpbp.2023.110847
IF: 5.201
2023-08-25
Progress in Neuro-Psychopharmacology and Biological Psychiatry
Abstract:Facial emotion (or expression) recognition (FER) is a domain of affective cognition impaired across various psychiatric conditions, including bipolar disorder (BD). We conducted a systematic review and meta-analysis searching for eligible articles published from inception to April 26, 2023, in PubMed/MEDLINE, Scopus, EMBASE, and PsycINFO to examine whether and to what extent FER would differ between people with BD and those with other mental disorders. Thirty-three studies comparing 1506 BD patients with 1973 clinical controls were included in the present systematic review, and twenty-six of them were analyzed in random-effects meta-analyses exploring the discrepancies in discriminating or identifying emotional stimuli at a general and specific level. Individuals with BD were more accurate in identifying each type of emotion during a FER task compared to individuals diagnosed with schizophrenia (SCZ) (SMD = 0.27; p -value = 0.006), with specific differences in the perception of anger (SMD = 0.46; p-value = 1.19e-06), fear (SMD = 0.38; p-value = 8.2e-04), and sadness (SMD = 0.33; p-value = 0.026). In contrast, BD patients were less accurate than individuals with major depressive disorder (MDD) in identifying each type of emotion (SMD = −0.24; p-value = 0.014), but these differences were more specific for sad emotional stimuli (SMD = −0.31; p-value = 0.009). No significant differences were observed when BD was compared with children and adolescents diagnosed with attention-deficit/hyperactivity disorder. FER emerges as a potential integrative instrument for guiding diagnosis by enabling discrimination between BD and SCZ or MDD. Enhancing the standardization of adopted tasks could further enhance the accuracy of this tool, leveraging FER potential as a therapeutic target.
pharmacology & pharmacy,neurosciences,psychiatry,clinical neurology